AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 212 min read$NAMS

NewAmsterdam Pharma Company N.V. along with its partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo…

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Ev

Original reporting
SEC EDGAR 8-K
Published Sep 21, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$NAMS
Bullish
high confidence
Mentioned
$NAMS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NAMSBullishMed
01

Why it matters

The approval unlocks revenue potential and milestone payments, positioning NewAmsterdam for significant upside if commercial uptake meets expectations.

02

Market read

Regulatory approval is a catalyst for price movement and sector re‑rating in European biotech.

03

What to watch

Post‑approval safety monitoring and the need for Menarini to execute commercialization effectively.

Relevance 8/10Novelty 8/10Timing: on Sep 21, 2026

Background

The 8‑K filing reports the first worldwide regulatory clearance for obicetrapib, a novel cholesterol‑lowering agent, and outlines licensing terms with Menarini.

Company-level read

Ticker impact

$NAMSBullishHigh confidence
Context

EU Commission granted marketing authorization for obicetrapib (Ubeslo) and its FDC (Evlarco) in Europe, marking the first global approval of the drug.

Expected impact

Potential upside as market anticipates revenue from EU sales and milestone payouts.

Evidence & confidence

First approval of a novel lipid‑lowering therapy; royalty stream and up to €833 million in milestones provide material upside.

Market effects

Sector

Boosts European lipid‑lowering drug sector and may pressure peers to accelerate their pipelines.

Regional

Strengthens European biotech exposure, especially for companies with EU approvals.

Global

First global approval could influence global cholesterol‑treatment market dynamics.

Counterpoint

What could challenge this read

Milestone payments are contingent on sales; market may overprice the approval before commercial data.

Key entities

  • company
    NewAmsterdam Pharma Co N.V.

    Biotech developer of obicetrapib.

  • company
    Menarini Group

    European partner with exclusive commercialization rights.

  • regulator
    European Commission

    Granted marketing authorizations across EU member states.

Read at source← All news

Related articles

SEP 29
$NAMSLowAI 8/10

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeabl

SEC EDGAR 8-K1 min
SEP 23
$NAMSMedAI 9/10

Is NewAmsterdam Pharma (NAMS) Undervalued After Its First Obicetrapib Approval?

NewAmsterdam Pharma (NAMS) received European Commission approval for its cholesterol drug obicetrapib, marking its first global regulatory approval. The stock has seen a recent bounce, up 3.28% to $23.32, following a period of decline. Analysts suggest the company may be undervalued with an implied fair value of $50.92, but risks include potential trial failures and equity dilution.

simplywall.st2 min
AUG 5
$NAMSMed

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20

SEC EDGAR 8-K7 min
JUL 24
$NAMSMed

NewAmsterdam, Menarini Cholesterol Drugs Receive Positive Opinion From CHMP

NewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.

rttnews.com3 min